Amicus Therapeutics (FOLD) Prelim. FY Revenue Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
January 9, 2023 7:00 AM ESTSignificant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022
2022 Full Year Revenue of ~$329M, Representing 16% YoY Growth at CER
Continued Double-Digit Growth in Galafold Revenue of 12-17% at CER Expected in 2023
Multiple Approvals and Launches Expected in 2023 for AT-GAA in Pompe Disease
On-Track to Achieve non-GAAP Profitability in 2H2023
PHILADELPHIA, Jan. 09, 2023 (GLOBE NEWSWIRE) --... More



